Subclinical signs of vascular damage relate to enhanced platelet responsiveness among nonpregnant formerly preeclamptic women

Circulating Fibronectin and Plasminogen Activator Inhibitor-2 Levels as Possible Predictors of Recurrent Placental Syndrome: An Exploratory Study

BACKGROUND/AIM

Placental syndromes (PS) are characterized by endothelial dysfunction complicating placental dysfunction. Possible markers for endothelial dysfunction and amount of trophoblast are fibronectin and plasminogen activator inhibitor-2 (PAI-2), respectively. We aimed (1) to determine whether in women with recurrent PS (rPS), this complication is preceded by deviating fibronectin- and PAI-2-levels, and (2) whether this is dependent on pre-pregnant plasma volume (PV).

METHODS

In 36 former patients, we determined fibronectin- and PAI-2-levels in blood-samples collected preconceptionally and at 12-16 weeks in their next pregnancy. Differences were analyzed between pregnancies with rPS (n = 12) and without rPS (non-rPS, n = 24) using linear mixed models, with subanalyses based on pre-pregnant normal or subnormal PV.

RESULTS

We observed higher fibronectin-levels at 12-16 weeks (p < 0.05 and p < 0.01, respectively) and lower PAI-2-levels at 16 weeks (p < 0.01) in the rPS subgroup, the intergroup differences being larger in women with subnormal PV.

CONCLUSION

We showed that former PS patients who developed rPS have raised fibronectin- and reduced PAI-2-levels already in early/mid pregnancy. These deviations are even more prominent in women with subnormal pre-pregnant PV, supporting development of a 2-step screening program for former patients to identify the high-risk subgroup of women who may benefit from closer surveillance.

Diseases in children born to mothers with preeclampsia: a population-based sibling cohort study

OBJECTIVE

We previously reported associations between preeclampsia and the occurrence of metabolic and respiratory diseases in the offspring. In this article we examine whether the associations were due to preeclampsia or factors leading to preeclampsia.

STUDY DESIGN

From 1978 through 2004, we identified 22,264 discordant sib-pairs in Denmark according to prenatal exposure to preeclampsia. Exposed children were compared to their unexposed siblings by using stratified Cox regression to estimate hazard ratios and 95% confidence intervals for metabolic and respiratory diseases.

RESULTS

Exposed children had rather similar risks for metabolic disorders compared to their unexposed siblings. However, when the second child within each sib-pair was exposed, this child had an increased risk for respiratory diseases (hazard ratio, 1.55; 95% confidence interval, 1.20-2.01).

CONCLUSION

Factors leading to preeclampsia may shape susceptibility to metabolic or respiratory diseases in the offspring but a programming effect on respiratory diseases induced by preeclampsia cannot be ruled out.

Obesity: a risk factor for preeclampsia

Obesity is becoming an epidemic worldwide. Among young women, obesity is especially important because maternal obesity confers an increased risk of preeclampsia, a hypertensive disorder of pregnancy and a leading cause of maternal and fetal morbidity and mortality. It is not known why obesity is a risk factor for preeclampsia, but these conditions might be related through common features related to oxidative stress, inflammation and altered vascular function. Recently, extensive vascular infiltration of neutrophils and vascular inflammation has been reported in both preeclamptic women and obese women. Therefore, if the vasculature of obese women is inflamed, they could be at increased risk of developing preeclampsia when they become pregnant and are exposed to the additional burdens of pregnancy.